定量血清IgA监测可更可靠评估多发性骨髓瘤疗效
该回顾性研究在491例IgA型多发性骨髓瘤患者中比较了血清蛋白电泳M蛋白与免疫比浊定量IgA的疾病监测价值,并开发验证了新的qIgA疗效评估标准。SPEP M蛋白谷值较qIgA中位提前41天出现,标准IMWG标准达到PR的中位时间短于qIgA标准(32 vs 58天,p<0.001)。qIgA标准可清晰区分达到PR与VGPR患者的无进展生存曲线,并倾向更早发现疾病进展。
要点
- IgA型MM中SPEP M蛋白定量因β迁移不可靠,qIgA监测可能更准确。
- SPEP M蛋白下降快于qIgA,基于M蛋白的IMWG标准可能误判疗效。
- qIgA疗效标准可更好分层进展风险并可能更早发现进展。
核心结论
- 基于SPEP M蛋白的IMWG标准监测IgA型MM可能产生虚假的疗效安心感。
- qIgA疗效标准能更准确按进展风险分层并可能更早检测疾病进展。
研究设计与样本
- 回顾性研究,纳入491例IgA型多发性骨髓瘤患者。
- 比较qIgA与SPEP M蛋白的疾病缓解动力学,并开发验证新的qIgA疾病评估标准。
主要发现
- SPEP M蛋白谷值中位较qIgA谷值提前41天(IQR 0-102)出现。
- 标准IMWG标准达到PR的中位时间短于qIgA标准(32 vs 58天,p<0.001)。
- 按qIgA标准分层(而非IMWG标准)可清晰分离达到PR或VGPR患者的无进展生存曲线。
- 使用qIgA较IMWG进展标准有一致趋势更早检测疾病进展。
关键数值与推荐
- SPEP M蛋白谷值较qIgA谷值中位提前41天(IQR 0-102)。
- IMWG标准达到PR中位32天,qIgA标准58天,p<0.001。
临床怎么用
- IgA型MM监测应考虑使用定量血清IgA而非仅依赖SPEP M蛋白。
- 采用qIgA疗效标准可能更准确评估进展风险并更早发现进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Unlike IgG monoclonal proteins (MCPs), IgA MCP quantification is unreliable due to beta-migration of IgA MCPs on serum protein electrophoresis (SPEP). The utility of nephelometric quantitative IgA (qIgA) to monitor IgA multiple myeloma (MM) is unclear. We retrospectively studied disease response kinetics using qIgA versus MCPs by SPEP, and developed and validated novel qIgA disease assessment criteria in 491 IgA MM patients. The SPEP MCP nadir occurred a median of 41 (IQR 0-102) days before the qIgA. The median time to achieve a partial response (PR) was shorter using standard IMWG versus qIgA response criteria (32 vs 58 days, p < 0.001). Stratification by qIgA criteria, unlike IMWG criteria, led to clear separation of the progression-free survival curves of patients achieving a PR or very good PR. There was a consistent trend toward earlier detection of disease progression using qIgA versus IMWG progression criteria. In conclusion, monitoring IgA MM using MCP-based IMWG criteria may be falsely reassuring, given that MCP levels on SPEP decrease faster than qIgA levels. The qIgA response criteria more accurately stratify patients based on the progression risk and may detect disease progression earlier, which may lead to more consistent measurement of trial endpoints and improved patient outcomes.
引用
- Visram A, Vaxman I, S Al Saleh A, et al. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia. 2021. PMID: 33623138. doi:10.1038/s41375-021-01180-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。